Predictive Markets on Drug Trials: Profit vs. Patient Safety and Scientific Integrity
Predictive market platforms Kalshi and Polymarket have expanded into pharmaceutical research, allowing users to place financial bets on the outcome of clinical trials and Food and Drug Administration (FDA) approval decisions.
The rise of these speculative contracts has drawn scrutiny from U.S. lawmakers concerned about potential threats to patient safety and scientific integrity.
The mechanism functions by transforming clinical trial results into binary financial contracts. A contract pays one dollar if a specific event occurs, such as the approval of a medication, and zero if it does not. The market price of the contract serves as an indicator of the probability that investors assign to that outcome. If a contract is priced at 30 cents, the market estimates a 30 percent chance of FDA approval.
Kalshi launched a pilot program last July in collaboration with the artificial intelligence firm AppliedXL. The company maintains that aggregating market predictions can help reveal information that would otherwise remain hidden. “The development of drugs is one of the most important sectors in the world and, at the same time, one of those in which the information available is most limited,” said Tarek Mansour, CEO of Kalshi.
Critics point to dangers regarding the use of non-public information. Researchers, pharmaceutical company employees, and federal regulators often possess data on trial results long before they are released to the public. This creates a structural advantage that may lead to insider trading, where informed participants bet against those without access to confidential data.
The potential for manipulation extends beyond financial markets into the conduct of the studies themselves. This creates a direct conflict of interest between financial gain and the objectivity required for medical research.
The integration of predictive markets into healthcare carries risks for the patients participating in clinical trials. According to JAMA, market-driven probabilities, presented as apparently precise percentages, could influence decisions to participate in a trial. A low probability of success could discourage recruitment, while overly optimistic valuations could fuel unjustified expectations. Adherence to therapies, study dropout, and switching from one treatment to another could also be affected by this information.
Kalshi has implemented internal safeguards, such as limiting contracts to late-stage trials and conducting checks to identify insider activity. However, the company is considering expanding its offerings to include early-stage trials and the number of adverse events reported to the FDA.
Senators Angela Alsobrooks and Ron Wyden sent a letter to Secretary of Health and Human Services Robert F. Kennedy Jr. requesting formal clarification on how the department intends to mitigate the risks associated with predictive markets.
The inquiry seeks detailed information regarding internal department communications, the participation of government employees in these betting platforms, and the nature of the relationship between the department and the Commodity Futures Trading Commission (CFTC), which oversees event-based contracts.
“Consentire alle persone di scommettere sul successo di queste sperimentazioni e di questi farmaci mina il processo scientifico, crea incentivi distorti per i ricercatori, danneggia i partecipanti agli studi e potrebbe provocar conseguenze mediche pericolose per un numero incalcolabile di americani,” the senators wrote in their correspondence.
As these platforms continue to grow, the fundamental question remains whether the pursuit of market-driven insights can coexist with the ethical requirements of medical science. The debate highlights a growing tension between the financialization of health outcomes and the protection of the patients who rely on the validity of clinical research.